A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder

BMC Medical Research Methodology

Volumn 9, Issue 1, 2009, Pages

  Lee, Soyon ^a   Malhotra, Bimal ^b   Creanga, Dana ^b   Carlsson, Martin ^b   Glue, Paul ^c  

^a RUTGERS UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; ANTIARRHYTHMIC AGENT; DRUG CARRIER;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; HUMAN; META ANALYSIS; OVERACTIVE BLADDER; PLACEBO EFFECT; SYSTEMATIC REVIEW; ANALYSIS OF VARIANCE; DRUG EFFECT; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE INCONTINENCE; URODYNAMICS;

ANALYSIS OF VARIANCE; ANTI-ARRHYTHMIA AGENTS; DRUG CARRIERS; HUMANS; MUSCARINIC ANTAGONISTS; PATIENT SELECTION; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URODYNAMICS;

EID: 69049085734     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-9-55     Document Type: Article

References (48)

1. Is the treatment of urgency incontinence a placebo response? Results of a five-year follow-up. M Aitchison R Carter P Paterson B Ferrie, Br J Urol 1989 64 478 80 10.1111/j.1464-410X.1989.tb05280.x 2611617
2. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. P Herbison J Hay-Smith G Ellis K Moore, BMJ 2003 326 841 4 12702614 10.1136/bmj.326.7394.841
3. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. G Nabi JD Cody G Ellis P Herbison J Hay-Smith, Cochrane Database Syst Rev 2006 4 CD003781 17054185
4. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. C Chapple V Khullar Z Gabriel JA Dooley, Eur Urol 2005 48 5 26 10.1016/j.eururo.2005.02.024 15885877
5. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. JH van Leeuwen R Castro M Busse BL Bemelmans, Eur Urol 2006 50 440 52 10.1016/j.eururo.2006.05.014 16753253
6. The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. I Yalcin RC Bump, Am J Obstet Gynecol 2004 191 194 7 10.1016/j.ajog.2004.03.089 15295364
7. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. CR Chapple V Khullar Z Gabriel D Muston CE Bitoun D Weinstein, Eur Urol 2008 54 543 62 10.1016/j.eururo.2008.06. 047 18599186
8. JPT Higgins S Green editors, Cochrane Handbookfor Systematic Reviews of Interventions Version 5.0.0 [updatedFebruary 2008] The Cochrane Collaboration 2008 http://www.cochrane-handbook.org
9. Trospium chloride 60 mg once daily (QD) for overactive bladder syndrome: results of a placebo-controlled interventional study. R Dmochowski P Sand NR Zinner DR Staskin, Urology 2008 71 449 454 10.1016/j.urology.2007.11.008 18342185
10. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. D Staskin P Sand N Zinner R Dmochowski, J Urol 2007 178 978 83 10.1016/j.juro.2007.05.058 17632131
11. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. P Abrams R Freeman C Anderström A Mattiasson, Br J Urol 1998 81 801 810 9666761
12. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. KL Burgio JL Locher PS Goode JM Hardin BJ McDowell M Dombrowski D Candib, JAMA 1998 280 1995 2000 10.1001/jama.280.23.1995 9863850
13. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. L Cardozo M Lisec R Millard O van Vierssen Trip I Kuzmin TE Drogendijk M Huang AM Ridder, J Urol 2004 172 1919 24 10.1097/01.ju.0000140729.07840.16 15540755
14. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo-and tolterodine-controlled phase 2 dose-finding study. CR Chapple P Arão JL Bosch D De Ridder AE Kramer AM Ridder, BJU Int 2004 93 71 7 10.1111/j.1464-410X. 2004.04561.x 14678372
15. YM-905 Study Group: Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. CR Chapple T Rechberger S Al-Shukri P Meffan K Everaert M Huang A Ridder, BJU Int 2004 93 303 310 10.1111/j.1464-410X.2004.04606.x 14764127
16. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. C Chapple P Van Kerrebroeck A Tubaro C Haag-Molkenteller HT Forst U Massow J Wang M Brodsky, Eur Urol 2007 52 1204 12 10.1016/j.eururo.2007.07.009 17651893
17. For The Transdermal Oxybutynin Study Group: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. RR Dmochowski GW Davila NR Zinner MC Gittelman DR Saltzstein S Lyttle SW Sanders, J Urol 2002 168 580 586 10.1016/S0022-5347(05)64684-8 12131314
18. Transdermal Oxybutynin Study Group: Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. RR Dmochowski PK Sand NR Zinner MC Gittelman GW Davila SW Sanders, Urology 2003 62 237 42 10.1016/S0090-4295(03)00356-X 12893326
19. The elderly patient with urge incontinence or urge-stress incontinence-efficacy and cardiac safety of propiverine. W Dorschner JU Stolzenburg R Griebenow M Halaska R Brünjes M Frank F Wieners, Aktuelle Urol 2003 34 102 8 10.1055/s-2003-38906 14566693
20. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. HP Drutz RA Appell D Gleason I Klimberg S Radomski, Int Urogynecol J Pelvic Floor Dysfunct 1999 10 5 283 9 10.1007/s001929970003 10543335
21. Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. M Halaska W Dorschner M Frank, Neurourol Urodyn 1994 13 428 30
22. Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (OAB) [abstract]. S Herschorn J Heessakkers D Castro-Diaz et al., Int Urogynecol J 1994 18 Suppl 1 S78
23. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. Y Homma JS Paick JG Lee K Kawabe, BJU Int 2003 92 741 7 10.1046/j.1464-410X.2003.04468.x 14616458
24. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. B Jacquetin J Wyndaele, Eur J Obstet Gynecol Reprod Biol 2001 98 97 102 10.1016/S0301-2115(00)00561-3 11516807
25. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial. KP Junemann S Al-Shukri, Neurourol Urodyn 2000 19 488 90
26. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. KP Jünemann E Hessdörfer I Unamba-Oparah M Berse R Brünjes H Madersbacher T Gramatté Urol Int 2006 77 334 9 10.1159/000096338 17135784
27. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release a randomized, placebo-controlled trial. V Khullar S Hill KU Laval HA Schiøtz U Jonas E Versi, Urology 2004 64 269 75 10.1016/j.urology.2004.02.029 15302476
28. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double-blind, placebo controlled study. KS Lee MS Choo JS Paick JG Lee JT Seo JZ Lee H Yoon CH Park Y Na YB Jeong JB Lee WH Park, Paper presented at: Annual Meeting of the International Continence Society; November 29 - December 1, 2006; Christchurch, New Zealand
29. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. H Madersbacher M Halaska R Voigt S Alloussi K Hofner, BJU Int 1999 84 646 51 10.1046/j.1464-410x.1999.00251.x 10510109
30. Tolterodine: a safe and effective treatment for older patients with overactive bladder. JG Malone-Lee JB Walsh MF Maugourd, J Am Geriatr Soc 2001 49 700 5 10.1046/j.1532-5415.2001.49144.x 11454106
31. A study of the significance of identifying detrusor instability in the treatment of overactive bladder symptoms. J Malone-Lee C Whately-Smith, Proceedings of the International Continence Society (ICS), 32nd Annual Meeting, Heidelberg, Germany 2002 228
32. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. R Millard J Tuttle K Moore J Susset B Clarke P Dwyer BE Davis, J Urol 1999 161 1551 5 10.1016/S0022-5347(05)68951-3 10210394
33. Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. VW Nitti R Dmochowski PK Sand HT Forst C Haag-Molkenteller U Massow J Wang M Brodsky T Bavendam, J Urol 2007 178 2488 94 10.1016/j.juro.2007.08.033 17937959
34. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. R Rackley JP Weiss ES Rovner JT Wang Z Guan 037 STUDY GROUP, Urology 2006 67 731 6 10.1016/j.urology.2005.10.061 16618562
35. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. L Rentzhog SL Stanton L Cardozo E Nelson M Fall P Abrams, Br J Urol 1998 81 42 8 9467475
36. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. D Robinson L Cardozo G Terpstra J Bolodeoku, BJU Int 2007 100 840 5 10.1111/j.1464-410X.2007.07162.x 17822465
37. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. R Rogers G Bachmann Z Jumadilova F Sun JD Morrow Z Guan T Bavendam, Int Urogynecol J Pelvic Floor Dysfunct 2008 19 1551 7 10.1007/s00192-008-0688-6 18685795
38. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. D Rudy K Cline R Harris K Goldberg R Dmochowski, Urology 2006 67 275 80 10.1016/j.urology.2005.08.017 16461077
39. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. JW Thüroff B Bunke A Ebner P Faber P de Geeter J Hannappel H Heidler H Madersbacher H Melchior W Schäfer, J Urol 1991 145 813 7 2005707
40. US PII study results: efficacy and safety of YM905, a bladder-selective treatment for OAB. T Uchida D Tempel S Ridge I Grimes N Smith, Int Urogynecol J 2002 13 S12
41. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. P Van Kerrebroeck K Kreder U Jonas N Zinner A Wein, Urology 2001 57 414 21 10.1016/S0090-4295(00)01113-4 11248608
42. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: A randomized placebo-controlled trial. A Wang S Chih M Chen, Urology 2006 68 999 1004 10.1016/j.urology.2006.05.038 17113893
43. Japanese Solifenacin Study Group: Randomized, double-blind, placebo-and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. O Yamaguchi E Marui H Kakizaki N Itoh T Yokota H Okada O Ishizuka S Ozono M Gotoh T Sugiyama N Seki M Yoshida, BJU Int 2007 100 579 87 10.1111/j.1464-410X.2007.07031.x 17669143
44. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. N Zinner M Gittelman R Harris J Susset A Kanellos S Auerbach, J Urol 2004 171 2311 5 10.1097/01.ju.0000127742.73136.0c 15126811
45. The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials - a secondary analysis. H Walach C Sadaghiani C Dehm D Bierman, BMC Med Res Methodol 2005 5 26 16109176 10.1186/1471-2288-5-26
46. A randomised, double-blind, placebo controlled trial of pelvic floor exercises in the treatment of genuine stress incontinence. IN Ramsay M Thou, Neurourol Urodyn 1990 9 398 9
47. Epidemiology and natural history of urinary incontinence. S Hunskaar EP Arnold K Burgio AC Diokno AR Herzog VT Mallett, Int Urogynecol J Pelvic Floor Dysfunct 2000 11 5 301 19 10.1007/s001920070021 11052566
48. Bias in meta-analysis detected by a simple, graphical test. M Egger GD Smith M Schneider C Minder, BMJ 1997 315 629 634 9310563